Skip to main content

Colon or Rectal Cancer, Stage I-III, Financial Burden Assessment (EAQ162CD)

Longitudinal Assessment of Financial Burden in Patients With Colon or Rectal Cancer Treated With Curative Intent



This research trial studies the financial burden in patients with stage I-III colon or rectal cancer who are undergoing treatment. Collecting data from patients about their cost and quality of life may help doctors to better understand the impact of cancer treatment on a patient's employment and finances.

Key Inclusion Criteria

Key Inclusion Criteria

For a patient to be eligible for participation in this study, all of the following criteria must apply.

  • Patients must have a life expectancy of >= 24 months
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3
  • Patients must have a newly diagnosed colon or rectal cancer (initial diagnosis, either a biopsy or curative surgery, whichever is most recent) within 60 days of registration and have not yet received radiation or chemotherapy
  • Patients must have stage I, II, or III disease at the time of enrollment and will be treated with curative-intent; this can be defined either clinically or pathologically if they have already undergone surgery; for staging of both colon and rectal cancer, the definition of stage I-III is based on the seventh edition (2010) or an updated version of the tumor, node, metastasis (TNM) staging system
  • Patients are not eligible if they are already enrolled on a treatment clinical trial at the time of registration; they can remain on the study if they subsequently enroll on a treatment clinical trial during the study time period
  • Patients who choose to not receive radiation and/or chemotherapy after a curative-intent surgery are eligible to participate
  • Patients with a history of previous malignancy (except non-melanoma skin or cervical in-situ cancer) treated (with either surgery, chemotherapy, and/or radiation) within the last 3 years are not eligible
  • Patients must be able to complete questionnaires in English
  • Patients must sign and give written informed consent in accordance with institutional and federal guidelines
Learn More

Learn More

To learn more, visit ClinicalTrials.Gov

Study Type

Phase: Observational

Principal Investigator(s)

Michael Humeniuk, MD


ECOG-ACRIN Cancer Research Group